Biotechnology

jCyte Inc. Announces Presentation of Phase 2b Results Evaluating jCell in Retinitis Pigmentosa at the American Society of Retina Specialists (ASRS) 2020 Virtual Annual Meeting

Biotechnology, Health, Pharmaceutical, Optical, Clinical trials, Ophthalmology, Vision, Blindness, Channelopathies, RTT, Retinitis pigmentosa, Organ systems, Retinitis, Retina

Tuesday, July 7, 2020 - 1:00pm

We are excited and privileged to have the opportunity to present for the first time, our Phase 2b data evaluating our investigational therapy jCell in retinitis pigmentosa at ASRS, said Paul Bresge, Chief Executive Officer, jCyte, Inc.

Key Points:

We are excited and privileged to have the opportunity to present for the first time, our Phase 2b data evaluating our investigational therapy jCell in retinitis pigmentosa at ASRS, said Paul Bresge, Chief Executive Officer, jCyte, Inc.
This years virtual ASRS scientific program provides a timely opportunity to share key clinical updates with the medical community.
Details of the virtual ASRS 2020 scientific presentation:
Oral Presentation: Intravitreal injection of allogeneic human retinal progenitor cells (jCell) for treatment of retinitis pigmentosa: Results from the Phase 2b trial
The presentation can be found at www.asrs.org .
jCyte, Inc. is a clinical-stage biotech company focused on developing jCell therapy for retinitis pigmentosa (RP) and other degenerative retinal disorders.

ProtoKinetix AAGP® Dry Eye Program Advancing

Health, Diabetes, Stem cells, Other Health, Clinical trials, Pharmaceutical, Biotechnology, RTT, Dry eye syndrome, Organ systems, Medical specialties, Medicine

Tuesday, July 7, 2020 - 1:30pm

ProtoKinetix, Incorporated ( www.protokinetix.com ) (the "Company" or "ProtoKinetix") (OTCQB: PKTX ), a clinical-stage biomedical company, provides the following update regarding upcoming news in its Dry Eye Disease Program.

Key Points:

ProtoKinetix, Incorporated ( www.protokinetix.com ) (the "Company" or "ProtoKinetix") (OTCQB: PKTX ), a clinical-stage biomedical company, provides the following update regarding upcoming news in its Dry Eye Disease Program.
Dry Eye Disease (DED) ProtoKinetix is expecting closure of agreements for the first steps in a roll-out of a new product line development that will test AAGP for treatments related to Dry Eye Disease.
We are pleased with the progress made with respect to the expansion of ProtoKinetixs Dry Eye Disease program.
It is important that each person reviewing this release understand the significant risks attendant to the operations of ProtoKinetix.

Cybin Corp. and IntelGenx Corp. Enter Into Feasibility Agreement for Fast-Acting, Orally-Dissolving Psilocybin Film

Alternative medicine, Mental health, Health, Other Health, Pharmaceutical, Biotechnology, Medicinal chemistry, Chemistry, Health sciences, Natural sciences, Pharmacokinetics, Entheogens, Bioavailability, Psilocybin, First pass effect

Tuesday, July 7, 2020 - 1:00pm

We at Cybin are proud to be working with IntelGenx to develop a fast-acting psilocybin film, said Cybins Chief Medical Officer, Dr. Jukka Karjalainen.

Key Points:

We at Cybin are proud to be working with IntelGenx to develop a fast-acting psilocybin film, said Cybins Chief Medical Officer, Dr. Jukka Karjalainen.
Compared to oral psilocybin capsules, which are subject to variable intestinal absorption and high first-pass metabolism in the liver, the systemic bioavailability of orally-dissolving psilocybin film is expected to be quite high.
In addition, the dose of psilocybin administered by an orally-dissolving film is expected to be a fraction of what is required in oral capsules.
Taken together, these features have the potential to increase both the safety and efficacy of psilocybin when administered in this manner.

Humanigen Appoints Senior Executives to Management Team

Tuesday, July 7, 2020 - 12:00pm

Humanigen, Inc. , (HGEN) (Humanigen), a clinical stage biopharmaceutical company focused on preventing and treating cytokine release syndrome (CRS) with lenzilumab, the companys proprietary Humaneered anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody, announced that several executives have been appointed to key positions at Humanigen.

Key Points:

Humanigen, Inc. , (HGEN) (Humanigen), a clinical stage biopharmaceutical company focused on preventing and treating cytokine release syndrome (CRS) with lenzilumab, the companys proprietary Humaneered anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody, announced that several executives have been appointed to key positions at Humanigen.
All three positions report to Cameron Durrant, MD, MBA, Chief Executive Officer, Humanigen.
He is also the founder of Black Horse Capital with decades of biotechnology investment experience.
We are pleased that both Dr. Chappell and Mr. Tousley, who have previously operated in interim capacities with the Company, have joined us as full-time members of the Humanigen team, stated Dr. Cameron Durrant.

MAIA Biotechnology, Inc. Announces Publication in Cancer Cell of Encouraging Data on the Immunogenic Effects of Its Flagship Product Candidate THIO

Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Medicine, Medical specialties, Clinical medicine, Immunology, Immunogenicity, Immunotherapy, Oncology, Biotechnology

Tuesday, July 7, 2020 - 1:00pm

Preclinical data have demonstrated that THIO kills cancer cells by targeting and uncapping telomeres thereby inducing DNA damage.

Key Points:

Preclinical data have demonstrated that THIO kills cancer cells by targeting and uncapping telomeres thereby inducing DNA damage.
The latest preclinical data showed this is complemented by an immunogenic effect, which may allow for more durable outcomes when used sequentially with immunotherapy.
In these preclinical studies published in Cancer Cell, investigators demonstrated that THIO leads to tumor regression through induction of innate and adaptive host immune system responses.
We believe the publication of these unprecedented immunogenic effects of THIO in Cancer Cell provides additional validation for this innovative program.

Aldeyra Therapeutics Announces New Drug Application (NDA) Development Plans for Dry Eye Disease

Health, Biotechnology, Medical specialties, Medicine, Drugs, Allergic conjunctivitis, Allergology, Combination drugs, Antidepressants

Tuesday, July 7, 2020 - 1:00pm

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases, today announced development plans to support a New Drug Application (NDA) for the novel investigational reactive aldehyde species (RASP) inhibitor reproxalap in dry eye disease.

Key Points:

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases, today announced development plans to support a New Drug Application (NDA) for the novel investigational reactive aldehyde species (RASP) inhibitor reproxalap in dry eye disease.
In addition, a safety trial in dry eye disease patients is expected to be initiated in the fourth quarter of 2020.
Reproxalap is a novel investigational small-molecule immune-modulating covalent inhibitor of RASP in development as a topically administered ophthalmic solution for dry eye disease and allergic conjunctivitis.
2016, 41(9):1143-9; Reproxalap preclinical and Phase 2a in dry eye disease clinical trial results on file.

Reven Publishes New COVID-19 Related Articles Outlining Clinical Impact Potential of Its RJX Platform

Health, Infectious diseases, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Medical specialties, Medicine, Health, Intensive care medicine, Respiratory diseases, Syndromes, Acute respiratory distress syndrome, Respiratory physiology, Respiratory distress syndrome, Infant respiratory distress syndrome, Clinical trial

Tuesday, July 7, 2020 - 1:09pm

Ph.D., and other members of the Reven team and their academic collaborators in the medical journal, Clinical Investigation (London).

Key Points:

Ph.D., and other members of the Reven team and their academic collaborators in the medical journal, Clinical Investigation (London).
The article also discusses the potential for the prevention of life-threatening complications from COVID-19 with RJX based on data obtained from clinical and non-clinical studies.
She provides the critical design elements for a two-cohort, two-part placebo-controlled, double-blind Phase 2 study of RJX in COVID-19 patients.
Clinical Impact Potential Of Rejuveinix (RJX) For Prevention Of Fatal Acute Respiratory Distress Syndrome (ARDS) And Multi-Organ Failure In Covid-19 Patients.

SCIEX Honors 50 Years of Innovation With Virtual Product Experience Launch

Technology, Research, Genetics, Software, Biotechnology, Health, Pharmaceutical, Data management, Science, Companies, Danaher Corporation, Applied Biosystems, Nordion

Tuesday, July 7, 2020 - 4:00pm

SCIEX , a global leader in life science analytical technologies, honors its 50th anniversary with the digital launch of pioneering products.

Key Points:

SCIEX , a global leader in life science analytical technologies, honors its 50th anniversary with the digital launch of pioneering products.
On July 10th, the first of its kind SCIEX virtual product experience will introduce products that enable customers to Run Fast, Go Beyond and Power Up .
I am incredibly proud of the progress SCIEX has achieved and look forward to continued innovation in the next 50 years.
Since 1970, the portfolio has grown through significant development and acquisitions, transitioning through the years from MDS SCIEX to Applied Biosystems to AB Sciex to SCIEX.

Walter Isaacson Interviews MIT President Emerita Susan Hockfield on Overcoming the COVID-19 “Diagnostics Deficit” and How Convergence of Biology and Technology Will Drive 21st Century Innovation

Tuesday, July 7, 2020 - 1:00pm

Dr. Hockfield is author of the new book The Living Machine: How Biology will Build the Next Technology Revolution.

Key Points:

Dr. Hockfield is author of the new book The Living Machine: How Biology will Build the Next Technology Revolution.
From then on, I just discovered so many new technologies emerging from the convergence of biology with engineering and the hard sciences.
Its an exciting story and I think it is going to be the technology story of the 21st century.
The countries that have managed to control the coronavirus are countries that have been able to track and trace.

Stephen Squinto, Ph.D., Named Vice Chairman of bioAffinity Technologies

Biotechnology, Medical devices, Health, Pharmaceutical, Oncology, University of Texas at San Antonio, Pharmaceutical industry in China

Tuesday, July 7, 2020 - 3:00pm

We are immensely pleased to have Dr. Squinto accept the position as Vice Chairman of the Board.

Key Points:

We are immensely pleased to have Dr. Squinto accept the position as Vice Chairman of the Board.
He joined bioAffinity Technologies from Southwest Research Institute where he helped develop the Institutes pharmaceuticals services and bioengineering business.
bioAffinity Technologies, Inc. ( www.bioaffinitytech.com ) is a privately held company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment.
Research and optimization of its platform technology are conducted in bioAffinity Technologies laboratories at the University of Texas San Antonio (UTSA).